Annexon Inc (ANNX) Unusual Options Activity Today

Checking ANNX unusual options activity helps you spot when traders are making outsized bets on Annexon Inc before the broader market catches on. Annexon Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor ANNX unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching ANNX unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking ANNX unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and ANNX unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis.

The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Catalysts rarely arrive without a footprint, and ANNX unusual options activity is often where that footprint shows up first. Our scanner tracks Annexon Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at ANNX unusual options volume on the call side or chasing put sweeps, Annexon Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.